<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04469517</url>
  </required_header>
  <id_info>
    <org_study_id>HIF in HHT</org_study_id>
    <nct_id>NCT04469517</nct_id>
  </id_info>
  <brief_title>Influence of Hypoxic Induced Factors in Patients With Hereditary Hemorrhagic Telangiectasia</brief_title>
  <official_title>Influence of Hypoxic Induced Factors in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Essen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Essen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with hereditary hemorrhagic telangiectasia (HHT) suffer from an inherited disorder
      leading to systemic vascular malformations. Mutations in several genes of the transforming
      growth factor (TGF)-β superfamily pathway influence angiogenesis in patients with HHT. The
      genetic loss of ALK1 or ENG alone are not sufficient to induce AVMs; environmental insults
      that could trigger angiogenesis (e.g. wounding) are also needed. In this study it will be
      analyzed if hypoxic induced factors could have an influence on the disease HHT.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hereditary hemorrhagic telangiectasia (HHT) is characterized by systemic vascular
      malformations leading to recurrent bleedings and shunt formation especially in the liver,
      lungs and the brain. The underlying pathogenic HHT mechanism remains unclear. The wide
      variability in age of onset and severity of symptoms amongst patients, even within the same
      family, suggests several factors contribute to the complexity of this disease. Mutations in
      several genes of the transforming growth factor (TGF)-β superfamily pathway influence
      angiogenesis in patients with HHT. The genetic loss of ALK1 or ENG alone are not sufficient
      to induce AVMs; environmental insults that could trigger angiogenesis (e.g. wounding) are
      also needed. In this study it will be analyzed if hypoxic induced factors could have an
      influence on the disease HHT.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Differences in hypoxic induced factors</measure>
    <time_frame>12 months</time_frame>
    <description>Differences in hypoxic induced factors analyzed in blood samples from patients with HHT and healthy controls</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation of level of hypoxic induced factors and disease severity</measure>
    <time_frame>12 months</time_frame>
    <description>Correlation of level of hypoxic induced factors in patients' blood sample and their disease severity</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hereditary Hemorrhagic Telangiectasia</condition>
  <arm_group>
    <arm_group_label>HHT</arm_group_label>
    <description>patients with HHT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <description>persons age- and sex matched who do not suffer from HHT nor their first or second degree relatives</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>hypoxic induced factors</intervention_name>
    <description>hypoxic induced factors analyzed in blood sample</description>
    <arm_group_label>HHT</arm_group_label>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with diagnosed hereditary hemorrhagic telangiectasie (HHT)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosed HHT (genetic testing and/ or fulfill at least 3 Curacao Criteria)

          -  older than 17 years

          -  ability to consent

        Exclusion Criteria:

          -  if inclusion Criteria are not met
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Freya Droege, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University hospital Essen Otorhinolaryngology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Freya Droege, MD</last_name>
    <phone>0049201 723</phone>
    <phone_ext>2481</phone_ext>
    <email>freya.droege@uk-essen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anna Wrobeln, PhD</last_name>
    <phone>0049201 723</phone>
    <phone_ext>4646</phone_ext>
    <email>anna.wrobeln@uk-essen.de</email>
  </overall_contact_backup>
  <reference>
    <citation>Kjeldsen AD, Vase P, Green A. [Hereditary hemorrhagic telangiectasia. A population-based study on prevalence and mortality among Danish HHT patients]. Ugeskr Laeger. 2000 Jun 19;162(25):3597-601. Danish.</citation>
    <PMID>11016284</PMID>
  </reference>
  <reference>
    <citation>Shovlin CL, Guttmacher AE, Buscarini E, Faughnan ME, Hyland RH, Westermann CJ, Kjeldsen AD, Plauchu H. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet. 2000 Mar 6;91(1):66-7.</citation>
    <PMID>10751092</PMID>
  </reference>
  <reference>
    <citation>Sánchez-Elsner T, Botella LM, Velasco B, Corbí A, Attisano L, Bernabéu C. Synergistic cooperation between hypoxia and transforming growth factor-beta pathways on human vascular endothelial growth factor gene expression. J Biol Chem. 2001 Oct 19;276(42):38527-35. Epub 2001 Aug 2.</citation>
    <PMID>11486006</PMID>
  </reference>
  <reference>
    <citation>Park SO, Wankhede M, Lee YJ, Choi EJ, Fliess N, Choe SW, Oh SH, Walter G, Raizada MK, Sorg BS, Oh SP. Real-time imaging of de novo arteriovenous malformation in a mouse model of hereditary hemorrhagic telangiectasia. J Clin Invest. 2009 Nov;119(11):3487-96. doi: 10.1172/JCI39482. Epub 2009 Oct 1.</citation>
    <PMID>19805914</PMID>
  </reference>
  <reference>
    <citation>Attisano L, Wrana JL. Smads as transcriptional co-modulators. Curr Opin Cell Biol. 2000 Apr;12(2):235-43. Review.</citation>
    <PMID>10712925</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 8, 2020</study_first_submitted>
  <study_first_submitted_qc>July 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2020</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Essen</investigator_affiliation>
    <investigator_full_name>Freya Droege</investigator_full_name>
    <investigator_title>Principle Investigator, Speaker of Westgerman HHT Center</investigator_title>
  </responsible_party>
  <keyword>hereditary hemorrhagic telangiectasia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telangiectasis</mesh_term>
    <mesh_term>Telangiectasia, Hereditary Hemorrhagic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

